Compare HXHX & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HXHX | DRMA |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 5.6M |
| IPO Year | 2022 | 2021 |
| Metric | HXHX | DRMA |
|---|---|---|
| Price | $0.17 | $0.67 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 739.5K | ★ 5.8M |
| Earning Date | 11-24-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $650.00 |
| P/E Ratio | $1.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.60 |
| 52 Week High | $1.36 | $4.66 |
| Indicator | HXHX | DRMA |
|---|---|---|
| Relative Strength Index (RSI) | 36.55 | 37.17 |
| Support Level | N/A | $0.64 |
| Resistance Level | $0.22 | $1.40 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 43.78 | 15.32 |
Haoxin Holdings Ltd is a China-based logistics company engaged in temperature-controlled transportation and urban delivery services. The company provides cold chain logistics, freight forwarding, and related transportation services for goods, including new energy materials, electronic products, pharmaceuticals, meat, fruits, and vegetables. Its principal revenue streams are temperature-controlled truckload services and urban delivery services.
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.